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ABSTRACT 
Protein Kinase C-iota (PKC-ι), an atypical protein kinase C isoform 
manifests its potential as an oncogene by targeting various aspects of cancer 
cells such as growth, invasion and survival.  PKC-ι confers resistance to drug-
induced apoptosis in cancer cells.  The acquisition of drug resistance is a major 
obstacle to good prognosis in neuroblastoma.  The focus of the dissertation was 
three-fold: First to study the role of PKC-ι in the proliferation of neuroblastoma.  
Secondly, to identify the efficacy of [4-(5-amino-4-carbamoylimidazol-1-yl)-2,3-
dihydroxycyclopentyl] methyl dihydrogen phosphate (ICA-1) as a novel PKC-ι 
inhibitor in neuroblastoma cell proliferation and apoptosis.  Finally, to analyze 
whether PKC-ι could self-regulate its expression.  Cyclin dependent kinase 7 
(Cdk7) phosphorylates cyclin dependent kinases (cdks) and promotes cell 
proliferation.  Our data shows that PKC-ι is an in-vitro Cdk7 kinase and that 
neuroblastoma cells proliferate via a PKC-ι/Cdk7/cdk2 cell signaling pathway. 
ICA-1 specifically inhibits the activity of PKC-ι but not that of PKC-zeta (PKC-ζ), 
the closely related atypical PKC family member. The IC50 for the kinase activity 
assay was approximately 0.1µM which is 1000 times less than that of 
aurothiomalate, a known PKC-ι inhibitor.  The phosphorylation of Cdk7 by PKC-ι 
was potently inhibited by ICA-1.  ICA-1 mediates its antiproliferative effects on 
neuroblastoma cells by inhibiting the PKC-ι/Cdk7/cdk2 signaling pathway.  ICA-1 
(0.1µM) inhibited the in-vitro proliferation of BE(2)-C neuroblastoma cells by 58% 
viii 
 
(P=0.01).  Additionally, ICA-1 also induced apoptosis in neuroblastoma cells.  
Interestingly, ICA-1 did not affect the proliferation of normal neuronal cells 
suggesting its potential as chemotherapeutic with low toxicity.  Hence, our results 
emphasize the potential of ICA-1 as a novel PKC-ι inhibitor and 
chemotherapeutic agent for neuroblastoma. 
Bcr-Abl has been shown to regulate the activation of the transcription 
factor ELK-1 which in turn regulates the expression of PKC-ι.  Alternatively, we 
hypothesize that PKC-ι can self regulate its expression by indirectly regulating 
the activity of Elk-1 in an ERK1 dependent manner.  Our preliminary data shows 
that there was robust increase in the expression as well as association of PKC-ι 
and Elk-1 in actively proliferating neuroblastoma cells suggesting a potential role 
of PKC-ι in regulating the activity of Elk-1.  Analysis of the subcellular fractions 
also presented a similar increase in the association between PKC-ι and Elk-1 in 
the nuclear fraction of actively proliferating cells as compared to cytoplasm.  
Interestingly, the nuclear expression of PKC-ι was also found to be higher in 
these cells, suggesting that PKC-ι translocated to the nucleus in actively 
proliferating cells and regulated the transcriptional activity of Elk-1.  However, our 
data from in-vitro kinase activity demonstrated that PKC-ι was not an Elk-1 
kinase but that it increased the phosphorylation of Elk-1 in the presence of ERK1, 
an upstream kinase of Elk-1 in the Bcr-Abl mediated regulatory pathway of PKC-
ι.  This suggested that ERK1 was integral to the self-regulatory activity of PKC-ι.  
In conclusion, we hypothesize that the self-regulatory mechanism of PKC-ι is 
initiated by the translocation PKC-ι into the nucleus where it activates ERK1.  
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This promotes the activation of its downstream target Elk-1 which subsequently 
upregulates the expression of PKC-ι 
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CHAPTER 1 
PROTEIN KINASE C 
1.1 Introduction 
Cells are normally subjected to strict regulatory mechanisms that limit cell 
division.  Protein kinases and protein phosphorylation control the entry and 
passage of cells through the cell cycle.  Cancer is the outcome of abnormalities 
in these mechanisms that lead to unchecked cell division.  The protein kinase C 
(PKC) family of Ser/Thr kinases is involved in transmembrane signal transduction 
pathways triggered by various extra and intracellular stimuli [1].  They were first 
discovered in bovine cerebellum by Yasutomi Nishizuka and colleagues in the 
1970s at Kobe University, Japan [2].  They are involved in the control of various 
cellular responses like proliferation, migration, apoptosis and survival of cells [3-
5].  The name PKC was coined by Nishizuka and coworkers as this enzyme was 
found to be activated by the Ca2+ dependent protease, Calpain [6].  Research 
following this has shown that PKCs not only require calcium for its activation but 
also co-factors like the lipid metabolite diacylglycerol (DAG) and 
phosphotidylserine (PS) [7-9]. 
1.2 PKC isozymes 
The PKC family consists of thirteen isozymes that can be classified into 
different groups on the basis of their co-factor requirements [10, 11].  Group I is 
the conventional PKCs (cPKC) which includes the isoforms alpha (α), beta I (βI), 
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beta II (βII) and gamma (γ).  They are also called classical isozymes as they are 
dependent on calcium, DAG and phospholipids for their activation.  Group II is 
the novel PKCs (nPKC) and is comprised of delta (δ), epsilon (ε), eta (η) and 
theta (θ).  They are termed novel because they are calcium independent but 
dependent on DAG and phospholipids.  The atypical PKC isozymes form the 
third group, so called because of their independence of calcium and DAG for 
their activation.  This group includes PKC zeta (ζ) and PKC iota (ι) in humans/ 
lambda (λ) in mouse.  An additional family member, Protein Kinase D, mu (μ) is 
introduced into the PKC family and is sometimes also referred to as an atypical 
isozymes [12].  Another distant related family member includes PKC-related 
kinases (PRK 1-3), known as PKN [13] 
1.3 Structure of Protein kinase C 
Protein kinase C family members have highly conserved carboxyl-terminal 
catalytic domain.  It is due to the structural similarity in the catalytic domain (also 
known as the kinase domain), that all PKC isozymes fall under one parent family.  
All the PKC isozymes differ from each other on the basis of their amino-terminal 
regulatory domain.  This domain is important for secondary messenger binding, 
recruiting the enzyme to the membrane and protein-protein interactions [7].  The 
first isozymes cloned were shown to possess four conserved sequences (C1-
C4), five variable sequences (V1-V5) and a pseudosubstrate region [14, 15].  
The regulatory and the kinase domain are linked to each other by a hinge region 
(V3) which is sensitive to cleavage by proteases. (Figure. 1). 
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1.3.1 The regulatory domain: The pseudosubstrate domain is located at 
the N-terminal adjacent to the C1 domain.  This region has a peptide-sequence 
similar to that of a substrate but lacks alanine in the phospho-acceptor position.  
In the inactive form of PKCs, the pseudosubstrate prevents complete activation 
of PKC by blocking the substrate binding pocket [16, 17].  The pseudosubstrate 
is released from kinase domain, following the activation of PKCs [18, 19]. 
The C1 domain is the membrane binding domain common in all the PKC 
family members [20].  cPKCs and nPKCs are comprised of two tandem repeats 
of cysteine-rich sequence termed as C1A and C1B respectively [21].  They are 
involved in the binding of secondary lipid messenger diacylglycerol and phorbol 
esters as well as membrane lipids [22, 23].  Atypical PKCs have only one 
cysteine rich C1 domain.  They lack the DAG and phorbol ester binding residues 
[20]. 
The C2 domain in cPKCs promotes their binding to anionic phospholipids 
in a Ca2+-dependent manner [24, 25].  nPKCs have a C2-like domain incapable 
of binding to Ca2+ due to absence of essential residues [26, 27].  However, the 
C2-like domain assists in protein-protein interactions.  A similar mechanism is 
also observed in PRKs [13, 28].  aPKCs lack the C2 domain but comprise of an 
additional PB1 domain which is known to function in protein-protein interaction 
[29].  
1.3.2 The catalytic domain: The catalytic domain is 40% homologous to 
the kinase domain of protein kinase A (PKA) and protein kinase B (AKT).  C3 and 
C4 motifs form the conserved sequences in this kinase core.  C3 domain 
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comprises the ATP binding site and C4 possesses the substrate binding 
sequence responsible for signal transduction [30].  
1.4 Protein kinase C regulation 
There are several important mechanisms that regulate complete 
maturation and activation of PKCs.  Primarily, the protein is phosphorylated at 
specific residues which release PKCs to the cytosol rendering it catalytically 
competent.  This initiates the translocation of the protein to the membrane in the 
presence of second messengers DAG, Ca2+, PS and phorbol esters. This is then 
followed by removal of pseudosubstrate exposing the substrate binding pocket. 
1.4.1 Regulation by Phosphorylation: The activation of PKC involves a 
cascade of three synchronized phosphorylations [31, 32] (Figure 2.2).  The first 
step is phosphorylation at the activation loop triggered by phosphoinositide-
dependent kinase -1 (PDK-1) that is upstream of PKC [33-38].  Phosphorylation 
at the activation domain rapidly initiates a chain reaction that involves 
autophosphorylation at the turn motif that further promotes the 
autophosphorylation at hydrophobic motif [34, 39].  The autophosphorylation at 
the turn motif is important in the maturation of PKC.  It protects the catalytically 
activated form of PKCs from thermal degradation as well as proteolysis [40, 41].  
Apart from being responsible for PKC activation, the turn motif is also important 
for protein-protein interaction as well as for initiating the mechanism of docking 
the enzyme to the membrane.  The autophosphorylation at hydrophobic motif 
[34, 39] marks the third and final step towards complete maturation of protein 
kinase C.  This serves to stabilize the protein from proteolytic degradation [42].   
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1.4.2 Regulation by secondary lipid messengers: Once phosphorylated, 
PKC is localized to the cytosol but is still inactive due to the presence of 
pseudosubstrate at its substrate binding pocket.  Upon extracellular stimulation, 
phospholipase C stimulates the breakdown of phosphatidylinositol into 
phosphatidylinositol 3- kinase (PI3k) and DAG followed by release of Ca2+fom 
the internal stores.  Ca2+ then binds to the C2 domain of cPKC inducing partial 
interaction with anionic phospholipids at the membrane.  This induces the protein 
to bind DAG via its C1 domain.  This high affinity interaction causes 
conformational changes in the protein, releasing the auto-inhibitory 
pseudosubstrate [43].  nPKCs do not have the Ca2+ binding C2 domain and 
hence depend on its C1 domain (particularly C1B) to build its strong interaction 
with the membrane.  aPKCs on the other hand do not respond to either DAG or 
Ca2+.  
1.4.3 Regulation by anchoring proteins: The distribution and localization of 
PKCs also regulate their overall biological functioning.  Proteins from the family 
of RACKs (receptors for activated C- kinase) bind different PKCs helping in their 
correct cellular localization and also increase their catalytic activity [44].  Another 
group of proteins called STICKs (substrates that interact with C-kinase) interact 
with immature,  
phosphorylated PKC bringing it close to PKC cofactors and release it when 
phosphorylated [45].  
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Figure 1.1 Structure of Protein Kinase C. The PKCs have highly conserved C-
terminal catalytic domain.  The three autophosphorylation sites are activation 
loop (A), turn motif (T) and hydrophobic motif (H).  The PKCs differ in the 
regulatory domains.  Conventional PKCs have C2 (Ca2+-binding domain), C1A 
(DAG-binding) domain, C1B (PS-binding) domain.  The novel PKCs have C-
domain similar to conventional PKCS.  The C2 domain is modified and incapable 
of binding to Ca2+, thus called C2-like.  The C1 domain of atypical PKCs bind to 
only PS.  Instead of the C2 domain, they have the PB1 domain that is involved in 
protein-protein interaction.  All PKCs have a pseudosubstrate domain in next to 
the N-terminal end.  Adapted from [46].  
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1.4.4 Protein kinase C Deregulation: Activation of protein kinase C is 
followed by its deactivation step.  Binding of co-factors to PKCs at membrane 
makes them catalytically competent. PKCs undergo conformational change 
removing the pseudosubstrate.  Association of DAG to PKC is transient.  At this 
point, the protein due to its open confirmation becomes highly sensitive to 
proteases like calpain and dephosphorylation by phosphatases like PP2A [47].  
Ultimately, protein kinase C is subjected to degradation via ubiquitin-proteosome 
pathway [48, 49]. 
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Figure 1.2 Activation of PKCs.  The first step in the activation of PKCs is the 
phosphorylating of activation loop (A) by PDK-1 at the C-terminal.  This triggers 
the rapid autophosphorylations at the turn motif (T) and hydrophobic motif (H), 
respectively.  This promotes the release of the PKC into the cytosol where it is 
maintained in the inactive form by binding of the pseudosubstrate (PS) to the 
substrate binding domain.  The subsequent steps in the activation of PKCs are 
triggered by signals that promote the lipid hydrolysis from the membrane and 
release cofactors such as Ca2+ and DAG.  These events promote the 
translocation of the PKCs to the membrane where the co-factors bind to the 
regulatory domains of PKCs.  Ca2+ binds to the C2 domain (orange) and DAG 
binds to C1 domain (blue).  The binding of the co-factors generate the energy 
required to release the pseudosubstrate form the substrate binding site and 
promote the downstream signaling.  Adapted from [46] 
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CHAPTER 2 
ROLE OF PKC-ι IN NEUROBLASTOMA  
2.1 Introduction 
Neuroblastoma is the most common extra-cranial tumor diagnosed in 
children.  Its origin lays in the sympathetic nervous system, that is, the network of 
nerves transmitting neuronal messages originating in the brain to the various 
parts of the body.  These highly lethal tumors comprise approximately 10% of all 
childhood cancers with a fatality rate of more than 15% [50].  As per the statistics 
of the American Cancer Society, approximately 650 new cases of neuroblastoma 
are diagnosed each year in the United States.  Spontaneous regression of the 
tumor or maturity into a benign ganglioneuroma is a characteristic feature of this 
cancer [51].  The etiology of this disease hitherto remains obscure.  The intensity 
of neuroblastoma lies in its primary target, infants and small children.  The 
prognosis in case of infants is much better as compared to children over a year.  
In the latter case, metastasis is often observed at the time of diagnosis and the 
subsequent recovery of the patient is rare [52].  Despite significant educational 
efforts, improved diagnostic techniques, and rigorous therapies, neuroblastoma 
control remains static.  Thus, justifying the importance of increased research to 
find a potential cure for this disease.  
The distribution of neuroblastoma is represented by Figure 2.1.  The 
primary site of neuroblastoma occurrence is the adrenal gland [53]. 
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Figure 2.1A Distribution of neuroblastoma in patients <1 year.  The chart 
represents the distribution of neuroblastoma by primary site in patients <1 years 
at diagnosis, among all races and both sexes.  Adapted from [53].  
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Figure 2.1B Distribution of neuroblastoma in patients >1year.  The chart 
represents the distribution of neuroblastoma by primary site in patients >1 years 
at diagnosis, among all races and both sexes.  Adapted from [53]. 
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The diagnosis, staging and treatment of neuroblastoma have been 
explained based on the International criteria for neuroblastoma diagnosis, 
staging and treatment [54, 55]. 
2.1.1 Diagnosis 
• X-rays  
• Bone scans  
• Computerized tomography (CT) scans  
• Magnetic resonance imaging (MRI) scans  
 2.1.2 Staging: Stage I represents tumor that is localized.  It can be totally 
removed with surgery.  The symptoms of this stage are that the tumor is confined 
within a particular body compartment such as abdomen, pelvis or neck.  
Stage IIA represents a tumor which is still localized.  However, the surgical 
removal is not very easy.  The symptoms are identical to Stage I.  
Stage IIB is where the tumor remains localized similar to Stage IIA and the 
surgical removal of tumor is not easy.  A major difference in Stage IIA and IIB is 
that in the latter, nearby lymph nodes show signs of tumor.  
Stage III represents an advanced stage.  By this time the surgical removal 
of the tumor is not possible.  Lymph nodes may or may not contain cancer cells. 
The tumor might have begun to metastasize. 
Stage IV is represented by metastasis. 
Stage IVS is a specialized stage associated with infants <1 year old.  
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Patients with this stage have a good chance of recovery.  Surprisingly, at this 
stage, neuroblastoma sometimes goes away on its own and may not require 
treatment.  
 2.1.3 Treatment: Surgery is usually the first choice of treatment; however, 
it is dependent on the location.  In case where the tumor is found to be attached 
to nearby vital organs like the lungs or the spinal cord, then surgery is considered 
too risky. 
Chemotherapy is the treatment option when surgery is risky. 
This may be used to promote the shrinking of the tumor to facilitate the surgical 
removal.  This treatment modality is generally used before surgery and before 
bone marrow stem cell transplant. 
Radiation therapy is used in the event of failure of surgery and 
chemotherapy, the next course of action is radiation therapy.  High-risk 
neuroblastoma patients may receive radiation therapy after chemotherapy and 
surgery to prevent cancer from recurring. 
Stem cell transplant is primarily used to replenish healthy cells.  This is 
accompanied by high doses of chemotherapy to kill any remaining cancer cells.  
 2.1.4 PKC-iota: PKC-ι was first identified in insulin-secreting rat cells 
RINm5F by Selbie et al. in 1993 [56].  It is 72% homologous to the other atypical 
family member PKC-ζ.  However, it is less than 54% homologous to other PKC 
isoforms [56].  The role of PKC in carcinogenesis came into the limelight with the 
discovery of PKC as a receptor for the tumor-promoting phorbol esters in the 
early 1980s [9, 57].  However, PKC-ι is the only PKC isoform that has been 
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successfully proven to be an oncogene [58, 59].  Among the PKCs, PKC-ι is the 
most common genomic amplicon as identified by comparative genomic 
hybridization [60].  The expression of PKC-ι has been reported to be elevated in 
many cancers such as lung [61], pancreas [62], gastric [63], esophagus [64], 
hepatocyte [65], breast [66], ovarian [67-69], prostate [70] and brain [71].  It 
promotes cell survival in non small cell lung cancer [72] and prostate cancer [73].  
PKC-ι has been known to induce resistance to drug mediated apoptosis in 
chronic myelogenous leukemia cells [74].  
PKCs have been shown to promote multi-drug resistance in 
neuroblastoma cells which has been a potent problem in the prognosis of 
neuroblastoma [75, 76].  Work from our lab has shown the importance of PKC-ι 
in glioma [71] and prostate cancer [73], thus, we were interested in analyzing  the 
role of PKC-ι in neuroblastoma.  
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Figure 2.2 Significance of PKC-ι as an oncogene.  Adapted from [59, 77].  The 
significance of PKC-ι lies in the fact that it can mediate numerous oncogenic 
signaling mechanisms in cells that promote invasion, proliferation and cell 
survival.  PKC-ι can be activated by a plethora of upstream targets such as 
dietary fats, EGF (epidermal growth factor), smoke carcinogens, Bcr-Abl and 
Ras. 
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2.2 Results 
 2.2.1 PKC-ι is overexpressed in neuroblastoma tissues: In order to 
analyze the role of PKC-ι in neuroblastoma we first determined the expression of 
PKC-ι in neuroblastoma tissues.  Our preliminary work performed on 
neuroblastoma tissues showed a 2.5-fold increase in PKC-ι in adrenal 
neuroblastoma compared to normal adrenal biopsies (P = 0.003, Figure 2.3 A, 
B).  β-actin loading controls demonstrated that approximately equal amounts of 
protein were loaded onto the SDS-PAGE.   
 2.2.2. PKC-ι is overexpressed in actively proliferating neuroblastoma cells: 
Furthermore, we tested the expression of PKC-ι in proliferating BE(2)-C cells.  
The PKC-ι expression levels were higher in 50% confluent cells (actively 
proliferating) than 100% confluent cells (contact inhibited and serum starved).  
Additionally, the expression of PKC-ζ, a closely related member of the atypical 
PKC family was analyzed.  There was no change in the expression of PKC-ζ in 
response to contact inhibition.  Caspase-3 expression levels were analysed to 
ensure that the decrease in the expression of PKC-ι was not an outcome of cells 
undergoing apoptosis (Figure 2.3 C, D).  These results suggest a potential role of 
PKC-ι in the proliferation of BE(2)-C cells. 
 2.2.3. Proliferation of neuroblastoma cells is PKC-ι dependent: The 
potential role of PKC-ι in the proliferation in BE(2)-C cells was confirmed via gene 
silencing using PKC-ι siRNA.  PKC-ι siRNA (150 nM) significantly reduced the 
cell proliferation by 53% at 48 hours (P=0.002) and by 65% at 72 hours 
(P<0.001) (Figure 2.3 E).  The expression of levels of PKC-ι was also reduces 
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significantly (P=0.04) (Figure 2.3F).  Expression levels of PKC-ζ remained 
invariant (Figure 2.3F).  These results indicate that PKC-ι plays an important role 
in the proliferation of neuroblastoma cells.  
2.3. Summary 
Previous work from our laboratory has found that PKC-ι is overexpressed 
in actively proliferating prostate cancer and glioma cells [71, 73].  Similarly, we 
found higher expression of PKC-ι in adrenal neuroblastoma tissue as well as 
neuroblastoma cells suggesting the involvement of PKC-ι in the proliferation of 
neuroblastoma cells.  Our data suggests that PKC-ι is involved in the proliferation 
of neuroblastoma cells.  Therefore, it is of interest to analyze whether there is a 
PKC-ι mediated proliferation pathway in neuroblastoma. 
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Figure 2.3 A, B. PKC-ι is overexpressed in neuroblastoma tissues.  (A) Normal 
and adrenal neuroblastoma tissue biopsies (60µg) were subjected to SDS-PAGE 
and Western blotting was performed with monoclonal antibodies against PKC-ι.  
(B) Densitometric analysis of representative immunoblots from 11 normal adrenal 
specimens and 11 adrenal malignant neuroblastomas are shown. 
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Figure 2.3 C, D PKC-ι is overexpressed in neuroblastoma cells.  (C) Endogenous 
levels of PKC-ι in BE(2)-C cells were determined by Western blot analysis and 
quantified using densitometry, respectively.  Equal amounts of cellular proteins 
(100µg) from actively proliferating (50%) and contact inhibited (100% S) cells 
were loaded in each well and immunoblotted for PKC-ι or PKC-ζ.  Caspase-3 
was analyzed to ensure that the effect on the levels of proteins was not due to 
apoptosis.  β-actin levels were analyzed as a loading control (D) Represents 
densitometry for the expression of PKC-ι in BE(2)-C cells.  
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Figure 2.3 E, F Effect of PKC-ι knockdown. BE(2)-C cells were treated with PKC-ι 
siRNA (150nM) for 24-72 hours as described in Materials and Methods.  At the 
indicated time points, viable cells were counted using Trypan blue exclusion 
assay.  The data represents n=3 independent experiments (E).  The same 
population of cells treated with either control siRNA or PKC-ι siRNA was 
immunoblotted for PKC-ι.  The levels of PKC-ζ were analyzed to determine the 
specificity of PKC-ι siRNA.  β-actin levels were analyzed as a loading control.  
Western blot represents N=3 independent experiments (F).  
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CHAPTER 3 
NEUROBLASTOMA CELLS PROLIFERATE VIA PKC-ι/Cdk7/cdk2 
PROLIFERATION PATHWAY 
3.1 Introduction 
Cyclin dependent kinases (cdks) are serine/threonine protein kinases that 
are mainly involved in regulation of the cell cycle.  The Cdk family is comprised of 
the following members: 
Cdk1 binds to cyclin A to form the M-phase promoting factor (MPF) and 
initiates mitosis [78].  Cdk1/cyclin A complex may also play a role in preparation 
of the cells for mitosis [79]. 
Cdk2 coordinates the transition from Gap1 phase to DNA synthesis phase 
(G1→S).  Cdk2/cyclin E complex triggers the initiation of DNA synthesis at the 
commencement of S-phase [78] 
 Interactions of Cdk1 and Cdk2 with cyclin B have been reported in G2 and 
M-phase of the cell cycle [80].   
CDK3 is closely related to Cdc2 and Cdk2 and has been reported to play 
a role in progression through Gap1 phase [81-83].  
Cdk4/cyclin D complex promotes the progression through the Gap1-phase.  
They regulate the cell cycle by suppressing the action of pRb protein. [84, 85]. 
Cdk5 is required during post-mitotic stages of neural differentiation [86, 
87].  
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Cdk6/cylin D complex promotes progression through the Gap1phase.  
They regulate the cell cycle by suppressing the action of pRb protein. 
Cdk4 and Cdk6 are termed as secondary Cdks since the cell cycle is not 
inhibited in the absence of these proteins [84, 85].   
Cdk7 is involved in the regulation of the activity of the cdks.  It is part of 
CAK (Cyclin dependent kinase activating kinase) complex [78, 88].  The only 
CAK identified in eukaryotes is Cdk7 [89]. 
Cdk8/cyclin C complex is involved in transcription by virtue of their 
association wih RNA polymerase II [90-93]. 
Cdk9/cyclin T complex is involved in transcription [94]. 
 3.1.1 Regulation of Cdks: The activation of cdks requires binding to cyclin 
as well as phosphorylation at conserved T residue by CAK [95, 96].  CAK is a 
trimeric complex composed of Cdk7, cyclin H and MAT1 [97-101].  CDK7 plays a 
dual role; first as CAK, it phosphorylates CDKs to promote cell-cycle and second 
as a component of the transcription factor TFIIH, it phosphorylates the C terminal 
domain (CTD) of Pol II [95].  Cdk7 regulates the cell-cycle by acting as an 
upstream regulator promoting a conformational change that enhances the activity 
of target cdks [102].  As part of the transcription machinery, CDK7 acts as a 
downstream effector kinase [103].  At mitosis, xeroderma pigmentosum disorder 
group D (XPD) promotes the sequestration of CAK from TFIIH releasing the 
trimetric CAK to act as a cell-cycle promoter [104].  The activation of Cdk7 is 
dependent on phosphorylation at two conserved sites.  Phosphorylation at T170 
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on the T-loop induces stable dimerization with cyclin H while phosphorylation at 
S164 on the activation loop promotes stabilization of CAK complex [105]. 
Deactivation of cdks is mediated by Cdk inhibitory subunits (CKIs) or 
regulatory kinases that phosphorylate the cdk subunit at inhibitory sites near the 
N terminus [106, 107].  CKIs can be divided into two main families:  
Cip/Kip forms the first group.  It includes p21, p27, and p57: They inhibit 
cdk2- and cdk4/6-cyclin complexes involved in G1 and G1/S control.  
 Ink4 family consists p15, p16, p18, and p19: They specifically inhibit cdk4 
and cdk6-cyclin D complexes.  
Thus, CKIs proteins are important in regulating the cell-cycle in response 
to unfavorable environmental conditions or intracellular signals such as DNA 
damage [108, 109]. 
Previous work in our laboratory demonstrated crosstalk between PKC-ι 
and Cdk7 in the regulation of the glioma cell cycle and prostate cancer cell 
proliferation [73, 110].   
From chapter 2 (Figure 2.3), we observed that PKC-ι is involved in the 
proliferation of neuroblastoma cells, therefore, we investigated whether the 
proliferation is via PKC-ι/Cdk7 pathway. 
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Figure 3.1 Cdks in cell-cycle. The figure represents major Cdks that participate in 
progression of cell cycle [78].  
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3.2 Results: 
 3.2.1 Cdk7 is a substrate for PKC-ι: Since, previous work from our 
laboratory demonstrated crosstalk between PKC-ι and Cdk7 [73, 110], we first 
determined the role of PKC-ι as an in-vitro kinase of Cdk7.  Recombinant PKC-ι 
was incubated with recombinant Cdk7 in an in-vitro kinase activity assay as 
described under Materials and Methods.  The data demonstrated that 
recombinant PKC-ι directly phosphorylated Cdk7 at T170 (Figure 3.2). A 60% 
increase in the phosphorylation of Cdk7 was observed (P=0.02).   
 3.2.2 BE(2)-C cells proliferate via the PKC-ι/Cdk7/cdk2 pathway: Next, we 
investigated whether PKC-ι plays a proliferative role in neuroblastoma through 
the Cdk7 pathway as shown in previous studies [110].  Our results show that 
PKC-ι directly associated with the phosphorylated forms of both Cdk7 (T170) and 
its downstream target cdk2 (T160) (Figure 3.3 A).  There was a significant 
increase in the levels of pCdk7 in co-immunoprecipitated (both PKC-ι and Cdk7) 
samples compared to individual immunoprecipitation. When compared with PKC-
ι alone, the increase was 37% (P= 0.05) and with immunoprecipitation of Cdk7 
alone it was 38% (P=0.001). The subsequent increase in the levels of pcdk2 
(T160) in co-immunoprecipitation samples were found to be 65% higher 
compared to immunoprecipitation of PKC-ι alone (P=0.01) and 37% for Cdk7 
(P=0.001).  These results suggest that Cdk7 may be a direct downstream 
substrate for PKC-ι in BE(2)-C cells.  To further analyze the role of PKC-ι as an 
in-vitro kinase of Cdk7, recombinant PKC-ι was incubated with 
immunoprecipitated Cdk7 in an in-vitro kinase activity assay as described 
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previously.  Recombinant PKC-ι directly phosphorylated Cdk7 at T170 (Figure 
3.3 B). A 70% increase in the phosphorylation of Cdk7 was observed (P=0.02).  
The property of PKC-ι to directly phosphorylate Cdk7 in BE(2)-C cells was 
confirmed by gene silencing using PKC-ι siRNA. Immunoblotting for pCdk7 
displayed that knockdown of PKC-ι by RNA interference lead to a 60% reduction 
in the phosphorylation of Cdk7 (P=0.03) (Figure 3.3 C). These results suggest 
that the proliferation of the neuroblastoma cells maybe mediated by the crosstalk 
between PKC-ι and Cdk7.  
 
 
 
Figure 3.2 PKC-ι directly phosphorylates. Cdk7 (A) Active PKC-ι (0.5μg) and 
active Cdk7 (0.5μg) were subjected to an in-vitro kinase activity assay.  The 
proteins were then separated by SDS-PAGE and Western blotted to determine 
the phosphorylation of Cdk7 at T170 and levels of pan-Cdk7.  Data represents 
N=3 independent experiments.   
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Figure 3.3 A, B BE(2)-C cells proliferate via the PKC-ι/Cdk7/cdk2 pathway.  (A, 
B) Column 1 represents negative controls (-).  The first negative control contains 
whole cell lysates (200μg) plus rabbit IgG whole molecule (50μl of 1:1 v/v) while 
the second negative control was comprised of whole cell lysates (200μg) plus 
rabbit IgG whole molecule (50μl) and normal rabbit IgG serum (5μg).  (A) PKC-ι 
and Cdk7 were immunoprecipitated separately as well as co-immunoprecipitated 
from whole cell extracts (200μg) using specific antibodies.  Western blot analysis 
was performed to determine pCdk7 at T170, pcdk2 at T160, pan-Cdk7, pan-cdk2 
and β-actin.  (B) Cdk7 (5μg) was immunoprecipitated from whole cell extracts 
(200μg), then subjected to an in-vitro kinase activity assay in the presence and 
absence of recombinant PKC-ι (0.5μg).  The proteins were then separated by 
SDS-PAGE and Western blotted to determine the phosphorylation of Cdk7 at 
T170 and levels of pan-Cdk7.   
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Figure 3.3 C. PKC-ι knockdown inhibits the PKC-ι/Cdk7/cdk2 pathway.  Column 
1 represents negative controls (-).  The first negative control contains whole cell 
lysates (200μg) plus rabbit IgG whole molecule (50μl of 1:1 v/v) while the second 
negative control was comprised of whole cell lysates (200μg) plus rabbit IgG 
whole molecule (50μl) and normal rabbit IgG serum (5μg).  Sub-confluent cells 
were treated with the siRNA complex (150nM) for 24 hours.  Subsequently, Cdk7 
was immunoprecipitated and the levels of pCdk7 and pan-Cdk7 in PKC-ι siRNA 
(PKC-ι) treated samples were compared with that of control siRNA (C) treated 
samples by Western blot analysis.  Data represents N=3 independent 
experiments. 
 
3.3 Summary 
Our data from in-vitro kinase activity assay demonstrates that PKC-ι is an 
in-vitro Cdk7 kinase.  Immunoprecipitation studies suggests that there is 
crosstalk between PKC-ι and Cdk7 in neuroblastoma cell line BE(2)-C cells and 
that the cells might be proliferating by the PKC-ι/Cdk7/cdk2 pathway.  The 
involvement of PKC-ι in the proliferation was confirmed via PKC-ι knockdown 
using siRNA which inhibited the phosphorylation of Cdk7.  Therefore, our data 
suggests that neuroblastoma cells proliferate via PKC-ι/Cdk7/cdk2 pathway.  
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CHAPTER 4 
ICA-1, A NOVEL PKC-ι INHIBITOR 
4.1 Introduction 
ICA-1 is a novel PKC-ι inhibitor.  ICA-1 is the abbreviation for [4-(5-amino-
4-carbamoylimidazol-1-yl)-2,3-dihydroxycyclopentyl] methyl dihydrogen 
phosphate.  PKC-ι is the only PKC isoform that has been proven to be an 
oncogene [58, 59]  PKC-ι mediates numerous signaling pathways that promote 
carcinogenesis (Figure 2.2).  It promotes cell survival in prostate cancer [73] and 
and drug resistance in chronic myelogenous leukemia cells [74]. However, there 
has been limited success in developing PKC-ι inhibitors.  Furthermore, PKC-ι and 
PKC-ζ are 84% homologous with respect to the amino acid sequences of their 
catalytic domain.  This sequence homology is a major hindrance in successfully 
designing an inhibitor that is specific to only PKC-ι and shall not inhibit PKC-ζ.  
Aurothiomalate (ATM) is only one FDA approved PKC-ι inhibitor [111] , certifying 
the need to develop more potent PKC-ι inhibitors.  ATM binds to the the PB1 
domain of PKC-ι and inhibits the protein-protein interaction of PKC and its 
downstream target.  However, since PKC-ι and PKC-ζ have highly conserved 
PB1 domain, ATM could induce non-specific inhibition of PKC-ζ.  ICA-1, was 
designed to bind to the unique sequence of amino acids (469-475) since, both 
PKC-ι and PKC-ζ exhibited heterogeneity in this particular sequence [56].   
30 
 
In the current study, we demonstrated that ICA-1 specifically targets the 
activity of PKC-ι with an IC50 of 10 nM in-vitro; however, it did not inhibit the 
activity of PKC-ζ.  Comparative study of the effect of ATM on the activity of PKC-ι 
versus PKC-ζ showed that ATM inhibited the activity of both the isozymes.  
Therefore, our data supports the potential of ICA-1 as a novel chemotherapeutic 
agent for cancer research.  
4.2 Results 
 4.2.1 Binding of ICA-1 to a sequence of amino acids in the catalytic 
domain of PKC-ι: To establish the therapeutic potential of PKC-ι as a drug target 
we screened compounds that would bind to a unique sequence in the catalytic 
domain of PKC-ι and inhibit its activity.  The sequence targeted comprised amino 
acid residues 469-475 (glutamine, isoleucine, arginine, isoleucine, proline, 
arginine and serine).  Molecular docking demonstrated the binding of ICA-1 
(Figure 4.1 A) to this sequence (Figure 4.1 B).   
 4.2.2 ICA-1 specifically inhibits the activity of PKC-ι: Since, PKC-ι and 
PKC-ζ are 84% homologous with respect to the amino acid sequences of their 
catalytic domain [56], our primary focus was to determine the specificity of ICA-1 
by performing a kinase activity assay to analyze the effects of ICA-1 on the 
activity of PKC-ι and PKC-ζ.  Recombinant active PKC-ι or PKC-ζ, was incubated 
with MBP (myelin basic protein), a known substrate for PKCs [112], in the 
presence or absence of ICA-1.  ICA-1 significantly inhibited the activity of PKC-ι 
by 16% at 0.1 µM (P= 0.03), 25% at 1 µM (P<0.05) and 45% at 5μM (P<0.002) 
(Figure 4.2 A).  However, ICA-1 did not have any significant effect on the activity 
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of PKC-ζ (Figure 4.2 C).  Furthermore, we made a comparative study between 
the specificity of ICA-1 and ATM for PKC-ι and PKC-ζ using a PKC activity assay 
kit.  ICA-1 significantly decreased the activity of PKC-ι (Figure 4.3 A) by 22.6% at 
0.1 µM (P=0.01), 53.47% at 1 µM (P=0.006) and 80% at 5 µM (P=0.002) but not 
PKC-ζ (Figure 4.3 B) demonstrating the selectivity of ICA-1 for PKC-ι and not 
PKC-ζ.  However, ATM at 100µM inhibited the activity of both PKC-ι by 67% 
(P=0.02) and PKC-ζ by 55 % (P=0.01) (Figure 4.3 C, D).  Lower concentrations 
of ATM had no significant effect on the activity of either of the enzymes.  The 
ICA-1 induced phosphotransferase inhibition was tested using a more sensitive 
γ-32P ATP method.  The IC50 obtained was approximately 10 nM (P=0.01) (Figure 
4.4). Collectively, these results show that ICA-1 is a specific PKC-ι inhibitor.  
 4.2.3 ICA-1 is a competitive inhibitor of PKC-ι: To test whether the 
inhibitory effect of ICA-1 on the activity of PKC-ι is competitive or non-
competitive, we analyzed the effect of ICA-1 by varying the concentration of MBP 
(0.0025mg/ml - 0.02 mg/ml).  Data from the Lineweaver- burke plot (Figure 4.5) 
show that the inhibitory effects of ICA-1 was inversely proportional to the 
substrate concentration suggesting that ICA-1 is a competitive inhibitor of PKC-ι.  
32 
 
 
Figure 4.1 Chemical structure and Molecular Docking of ICA-1. (A) The structure 
of ICA-1 [4-(5-amino-4-carbamoylimidazol-1-yl)-2,3-dihydroxycyclopentyl]methyl 
dihydrogen phosphate.  It has a molecular weight of 336.18 g/mol and is soluble 
in water.  (B) Molecular docking of ICA-1 on amino acid residues 469 - 475 of the 
catalytic domain of PKC-ι. 
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Figure 4.2 A, B, C, D.  ICA-1 specifically inhibits the activity of PKC-ι.   
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Figure 4.2 A, B, C, D.  ICA-1 specifically inhibits the activity of PKC-ι.  
Recombinant active PKC-ι (A) or PKC-ζ (C) (0.01µg/µl) was incubated with 
myelin basic protein (5μg) in the presence or absence of ICA-1 (0.1μM, 1µM and 
5μM) in a kinase activity assay.  (A, C) Show the Western blot analysis for the 
effect of ICA-1 on the activities of PKC-ι and PKC-ζ respectively.  Western blots 
represents N=3 independent experiments.  (B, D) represent the densitometry for                         
effect of PKC-ι and PKC-ζ activity respectively, upon ICA-1 treatment.  
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Figure.4.3 A, B, C, D. Comparison between ICA-1 and ATM.  Recombinant PKC-
ι or PKC-ζ (0.01μg/μl) was treated with different concentrations of ICA-1 (A, B) or 
ATM (C, D) for 10 min at 4°C followed by incubation with phosphatidylserine and 
ATP for 30 min at 30°C.  Data represents N=3 independent experiments.  
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Figure 4.4 IC50 of ICA-1.  Recombinant PKC-ι (0.01µg) was treated with different 
concentrations of ICA-1 for 10 min at 4°C followed by incubation with PIP3 for 10 
min at 30°C.  Data represents N=2 independent experiments. 
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Figure 4.5 Competitive inhibition of PKC-ι activity by ICA-1.  Recombinant active 
PKC-ι (0.01μg/μl) was incubated with varying concentrations of MBP (0.0025 
mg/ml, 0.05 mg/ml, 0.010 mg/ml and 0.02 mg/ml) in the presence or absence of 
ICA-1 (1 µM) followed by detection by ELISA based assay. Data represents N=3 
independent experiments. 
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4.3 Summary 
 ICA-1 specifically inhibits the activity of PKC-ι and did not have any 
significant effect on activity of PKC-ζ.  Comparison with the FDA-approved PKC-ι 
inhibitor, ATM showed that ICA-1 is a more potent and specific PKC-ι inhibitor.  
The inhibitory action of ICA-1 is competitive.  This is very important since, it 
suggests that the mode of action of ICA-1 may not involve ATP- competitive 
binding.  Thus, our data suggests that ICA-1 is an interesting agent to be tested 
on neuroblastoma cell which proliferate via PKC-ι mediated pathway. 
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CHAPTER 5 
ICA-1 INHIBITS PROLIFERATION AND INDUCES APOPTOSIS OF 
NEUROBLASTOMA CELLS 
5.1 Introduction 
Neuroblastoma is the most common extra cranial tumor diagnosed in 
children and in infants [113].  They are multidrug resistant tumors and show poor 
prognosis [114].  The primary target of the disease is infants and small children.  
The prognosis in is much better in infants as compared to children over a year 
whereas in the  latter recovery of the patient is rare [52].  Despite significant 
research efforts and advanced therapeutic regiments, neuroblastoma control 
continues to be a medical dilemma. 
We demonstrate that the neuroblastoma cells proliferate via PKC-
ι/Cdk7/cdk2 pathway.  ICA-1 treatment resulted in inhibition of this pathway. 
Treatment with ICA-1 induced chromatin condensation as shown by 4 ′, 6-
diamidino-2-phenylindole (DAPI) staining of the nucleus.  ICA-1 also induced 
DNA fragmentation which was analyzed using 3′ terminal 
deoxynucleotidyltransferase (TdT)- mediated dUTP nick end-labeling (TUNEL) 
assay depicting the pro-apoptotic potential of ICA-1.  Furthermore, ICA-1 
promoted apoptosis of neuroblastoma cells via induction of Caspase-3 activation 
and subsequent cleavage of PARP. 
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5.2 Results 
 5.2.1 ICA-1 inhibited the proliferation of BE(2)-C neuroblastoma cells: 
Since, our results (Figure 3.3) demonstrated the role of the PKC-ι/Cdk7/cdk2 
pathway in the proliferation of neuroblastoma cell line BE(2)-C, we hypothesized 
that treatment with ICA-1 should inhibit the proliferation of these cells.  We 
analyzed the effect of ICA-1 on normal neuronal cells LA1-5s and the 
neuroblastoma BE(2)-C cell line.  Cell viability assays showed that ICA-1 had no 
significant effect on the proliferation of LA1-5s cells (Figure 5.1 A), but 
significantly inhibited the proliferation of the neuroblastoma cell line, BE(2)-C by 
58% at 48 hours (P=0.01) with an IC50 of 0.1µM (Figure 5.1 B).  Furthermore, we 
made a comparative study between the effects of ICA-1 with that of ATM on the 
two cell lines.  Interestingly, we found that ATM (100µM) inhibited the 
proliferation of BE(2)-C (Figure 5.2 A).  However, this concentration also inhibited 
the proliferation of LA1-5s cells (Figure 5.2 B).  
 5.2.2 ICA-1 inhibited the in-vitro phosphorylation of Cdk7 by PKC-ι:  Since, 
ICA-1 specifically inhibited PKC-ι activity and PKC-ι is an in-vitro Cdk7 kinase, 
we investigated the effect of ICA-1 on phosphorylation of Cdk7.  ICA-1 inhibited 
the in-vitro phosphorylation of Cdk7 by recombinant PKC-ι (Figure 5.3). 
 5.2.3 ICA-1 inhibited the proliferation of BE(2)-C neuroblastoma cells  by 
abrogating the PKC-ι/Cdk7/cdk2 pathway: In order to prove that the molecular 
mechanism of ICA-1 is inhibition of the PKC-ι/Cdk7/cdk2 pathway, we analyzed 
the effect of ICA-1 (0.1µM) in cell culture.  BE(2)-C cells were treated with ICA-1 
(0.1µM) for 48 hours with addition of drug every 24 hours.  ICA-1 inhibited the 
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phosphorylation of Cdk7 by 55% (P=0.001) which further down regulated the 
phosphorylation of cdk2 by 65% (P=0.01) (Figure 5.4).  Therefore, our data 
reveal the possible mechanism by which ICA-1 exhibits its anti-proliferative effect 
on BE(2)-C cells. 
 5.2.4 ICA-1 induces apoptosis in BE(2)-C cells: Since, ICA-1 inhibited the 
proliferation of neuroblastoma cells; we tested whether the drug could induce 
apoptosis in these cells.  BE(2)-C cells treated with ICA-1 (0.1µM) exhibited 
chromatin condensation and nuclear fragmentation compared to control cells as 
displayed by nuclear staining with DAPI (Figure 5.5 A, B). DNA damage following 
ICA-1 treatment was also detected as shown by TUNEL assay.  The increase in 
fluorescence in response to ICA-1 treatment represents the increase of free 3 ′ 
OH groups of cleaved DNA (Figure 5.5 C, D).  Because ICA-1 induced apoptosis 
in neuroblastoma, we further determined whether ICA-1 also induces other 
apoptotic responses such as Caspase and PARP cleavage.  Treatment of BE(2)-
C with ICA-1 (0.1µM) induced cleavage of Caspase-3 as shown by Western blot 
analysis (Figure 5.5 E).  PARP, a downstream target for Caspase-3 was also 
cleaved in response to ICA-1 treatment (Figure5.5 E). Thus, our data strongly 
suggests that ICA-1 induces apoptosis in BE(2)-C neuroblastoma cells. 
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Figure 5.1 A, B ICA-1 inhibits the cell proliferation of BE(2)-C neuroblastoma 
cells.  LA1-5s and BE(2)-C cells (5x104) were treated with ICA-1 (A, B) from 24-
72 hours.   At the indicated time points, viable cells were counted using Trypan 
blue exclusion assay.  The control cells were incubated with equal volume of 
vehicle control (sterile water).  Data represents N=3 independent experiments 
and the mean number of viable cells and standard error were plotted.   
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Figure 5.2 A, B ATM inhibits the cell proliferation of both normal neuronal and 
neuroblastoma cells.  LA1-5s and BE(2)-C cells (5x104) were treated with ATM 
(A, B) from 24-72 hours.   At the indicated time points, viable cells were counted 
using Trypan blue exclusion assay.  The control cells were incubated with equal 
volume of vehicle control (DPBS).  Data represents N=3 independent 
experiments and the mean number of viable cells and standard error were 
plotted.  
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Figure 5.3 A, B ICA-1 inhibited the in-vitro phosphorylation of Cdk7 by PKC-ι.  (A) 
Recombinant active PKC-ι (0.5µg) and active Cdk7 (0.5µg) were subjected to an 
in vitro kinase activity assay in the presence of ICA-1 (0.1µM and 5µM). The 
expression of pCdk7 (T170) and pan-Cdk7 were determined by Western blot 
analysis.  (B) Represents the densitometry for the effect of ICA-1 on the in-vitro 
phosphorylation of Cdk7 by PKC-ι. Data represents N=3 independent 
experiments. 
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Figure 5.4 A, B ICA-1 abrogated the PKC-ι/Cdk7/cdk2 pathway.  (A) BE(2)-C 
cells treated with ICA-1 (0.1µM) for 48 hour were harvested and whole cell 
extracts were prepared.  Equal protein (100μg) was loaded on SDS-PAGE 
followed by immunoblotting for pCdk7 (T170) and pcdk2 (T160) pan-Cdk7, pan-
cdk2, PKC-ι and β-actin to examine the difference between control cells (-) and 
ICA-1 treated cells (+).  (B) Represent the densitometry for the decrease in the 
pCdk7 and pcdk2 upon ICA-1 treatment.  Data represents N=3 independent 
experiments.  
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Figure 5.5 A, B, C, D ICA-1 induces apoptosis in BE(2)-C cells.  (A, C) depict 
cells treated with vehicle control. (B, D) depict cells treated with ICA-1 (0.1µM).  
(A, B) Cells were stained with DAPI to visualize the cellular nuclei.  (C, D) Cells 
were subjected to TUNEL assay.  Data represents N=3 independent 
experiments. 
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Figure 5.5 E ICA- 1 induces apoptosis in BE(2)-C cells.  (E) BE(2)-C cells were 
treated with either vehicle control or ICA-1 (0.1µM) for 24, 48 and 72 hours.  At 
the indicated time points, whole cell extracts were prepared followed by SDS-
PAGE and subsequently Western blotting for Caspase-3 activity and PARP 
cleavage.  β-actin levels were used as loading control.  Data represents N=3 
independent experiments. 
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5.3. Summary 
 ICA-1 specifically inhibited the proliferation of neuroblastoma cells and did 
not have a significant effect on the proliferation of normal neuronal cells.  
However, ATM inhibited the proliferation of both cells.  Thus, our data supports 
that ICA-1 is less toxic than ATM.  ICA-1 inhibited the capacity of PKC-ι as an in-
vitro Cdk7 kinase as well as inhibited the PKC-ι/Cdk7/cdk2 pathway in BE(2)-C 
cells.  The inhibition of proliferation was accompanied by induction of apoptosis.  
Thus, ICA-1 inhibits the proliferation and induces apoptosis in 
neuroblastoma cells. 
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CHAPTER 6 
SELF REGULATION OF PKC-ι 
6.1 Introduction 
PKC family of serine/threonine kinases are involved in many cellular 
responses such as proliferation, differentiation, motility, and survival.  Different 
PKC iosoforms have been reported to be involved in different types of cancers 
like brain, neuroblastoma, prostate, etc. [115].  However, the knowledge 
regarding the transcriptional and translational regulation of PKCs is still 
rudimentary.  The promoters of several PKCs (α, β, γ) have been cloned till date, 
but few have been linked to cancer [116-120].  Among the PKC family, PKC-ι is 
the only isoform that has been proven to be an oncogene [58, 59].  It is the most 
common genomic amplicon as identified by comparative genomic hybridization 
[60].  The expression of PKC-ι has been reported to be elevated in many cancers 
such as lung [61], breast [66], ovarian [67-69], prostate [70], brain [71], etc.  The 
expression of PKC-ι is regulated by Bcr-Abl [121]. 
 6.1.1 Bcr-Abl: The translocation of the abl tyrosine kinase gene from the 
long arm of chromosome 9 to the breakpoint cluster region (bcr) of chromosome 
22, the Philadelphia chromosome is the genetic cause of Chronic myelogenous 
leukemia (CML) [122].  Ninety five percent of CML patients test positive for the 
mutation in Philadelphia chromosome [123].  Numerous forms of bcr-abl result 
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from various breakpoints in the bcr genes [123].  The 210-kDa p210bcr-abl gene 
is the most common form while 185-kDa p185bcr-abl is diagnosed in 25% of 
CML patients [123].  Bcr-Abl regulates a plethora of signaling pathways, 
however, resistance to apoptosis associated with Bcr-Abl-is dependent on the 
Ras/MEK and PI 3-kinase pathways [124, 125] (Figure.6.1)  Among the PKC 
family, PKCβII is essential for Bcr-Abl mediated CML cell proliferation whereas 
PKCι promotes Bcr-Abl-mediated resistance to drug-induced apoptosis [121, 
126, 127].  
 
 
Figure 6.1 Bcr-Abl activates both PI3K and MAPK pathways.  Adapted from 
[124]  
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Activation of the ELK-1 consensus sequence near the promoter region of 
PKC-ι is it the target of Bcr-Abl in the regulation  of PKC-ι expression [121].  
Regulation of PKC-ι by Bcr-Abl has been shown to regulate the activation of the 
transcription factor ELK-1 which is downstream of Ras/MEK pathway [121].  
(Figure 6.2) 
 
 
Figure 6.2 Bcr-Abl mediated regulation of PKC-ι expression.  Adapted from [128]  
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 6.1.2 Ets family: Ets family of transcription factors play vital role in 
coordinating cellular responses and gene expression [129]. A characteristic 
feature of the Ets family is a conserved winged helix-turn-helix DNA binding 
domain [130-132].  They are the downstream target of MAPK pathways [131].   
The Ets family can be divided into two major groups [129]. 
  The first group is comprised of Ets1, Ets2 and Pointed.  These have a 
conserved C-terminal DNA binding domain and a N-terminal domain referred to 
as pointed domain which houses the single MAP phosphorylation site [133, 134] 
  The second group is the ternary complex factors (TCFs):  These include 
Elk1, Sap1a, Sap1b, Fli1and Net. They have a transactivation domain that can 
be phosphorylated by MAPK at multiple serine and threonine residues. [135, 
136]. 
The Ets family mediate their transcriptional activity by binding to specific 
sequences called the Ras-response element (RRE) or serum-response elements 
(SRE) that are located near the promoter region of various genes [129].  
 6.1.3 Elk-1: Among the Ets family members, Elk-1 is a crucial molecule 
because it is activated by all three MAPK pathways, namely, p38, JNK and ERK 
[137-139].  JNK and ERK phosphorylate different residues in the C-domain of 
Elk-1 while the docking site for p38 is still unknown [140, 141].  
Alternate to the Bcr-Abl mediated regulation of PKC-ι expression, we 
hypothesize that PKC-ι may self regulate its expression by directly associating 
with ERK and promoting its translocation to the nucleus where it activates the 
transcription factor Elk-1. 
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6.2 Results 
 6.2.1 Expression of PKC-ι and Elk-1 is higher in actively proliferating 
neuroblastoma cells: To analyze whether there is a correlation between the 
expression profile of PKC-ι and Elk-1 in neuroblastoma, we primarily determined 
the expression of PKC-ι and Elk-1 in neuroblastoma cells.  The expression of 
PKC-ι was higher in actively proliferating malignant neuroblastoma BE(2)-C and 
LA-55n cells as compared to serum starved cells.  However, the expression of 
PKC-ι in non-malignant neuroblastoma LA-15s cells was reverse, that is, PKC-ι 
expression in actively proliferating cells was less than serum staved cells.  Next, 
we analyzed the expression of the transcription factor Elk-1 in these cells.  The 
expression of Elk-1 corresponded with the expression profile of PKC-ι.  In case of 
malignant neuroblastoma cells, Elk-1 expression was higher in actively 
proliferating cells while in non-malignant cells, the expression was higher in 
serum starved cells (Figure.6.3).  
 The data suggests that there is correlation between expression of PKC-ι 
and Elk-1 in neuroblastoma. 
 6.2.2 PKC-ι directly associated with Elk-1 in actively proliferating cells: 
Since, there was a correlation between expression of PKC-ι and Elk-1 in 
neuroblastoma, we further analyzed if there was an association between the two 
proteins.  Immnunoprecipitation studies showed that the association between 
PKC-ι and Elk-1 coincided with the expression pattern of the two proteins in 
neuroblastoma cells.  The association was higher in actively proliferating 
malignant neuroblastoma BE(2)-C and LA-55n cells as compared to serum 
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starved cells.  However, the expression of PKC-ι in non-malignant neuroblastoma 
LA-15s cells was reversed, the association was more robust in serum staved 
cells than actively proliferating cells (Figure.6.4).   
 Thus, our data suggests a crosstalk between PKC-ι and Elk-1. 
 6.2.3 Subcellular association of PKC-ι and Elk-1: Since, the association 
between PKC-ι and Elk-1 was higher in actively proliferating malignant 
neuroblastoma cells; we analyzed the subcellular association between the two 
proteins.  Our hypothesis was that PKC-ι would associate with cytoplasmic Elk-1 
and promote its nuclear translocation.  The association of PKC-ι and Elk-1 was 
higher in the nuclear fraction of actively proliferating BE(2)-C neuroblastoma cells 
suggesting that PKC-ι may not influence the nuclear translocation of Elk-1 
(Figure 6.5). 
 6.2.4 Sub-cellular expression of PKC-ι and Elk-1: Since the nuclear 
association between PKC-ι and Elk-1 was more robust than their cytoplasmic 
association, our new hypothesis was that PKC-ι could translocate into the 
nucleus and directly activate the transcription factor Elk-1.  Thus, the rationale 
was that the nuclear expression of the two proteins should be higher in activlely 
proliferating cells.  Analysis of the subcellular fractions of actively proliferating 
LA1-55n and BE(2)-C malignant neuroblastoma cells demonstrated that the 
expression of PKC-ι was higher in the nucleus as compared to the cytoplasm.  In 
the case of serum starved cell, the expression of PKC-ι was higher in the 
cytoplasm (Figure 6.6 A, B).  This data suggested that in actively proliferating 
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neuroblastoma cells, PKC-ι translocates to the nucleus and directly activates the 
transcriptional activity of Elk-1. 
 6.2.5 PKC-ι indirectly phosphorylates Elk-1: In order to test our hypothesis 
that PKC-ι can directly activate Elk-1, we analyzed the capacity of PKC-ι as an 
Elk-1 kinase.  Recombinant active PKC-ι did not directly phosphorylate 
recombinant active Elk-1.  However, the phosphorylation of Elk-1 by ERK1 was 
increased in the presence of recombinant active PKC-ι (Figure 6.7).  This 
suggested that PKC-ι could indirectly promote the phosphorylation of Elk-1 in 
ERK-1 dependent manner.  
 6.2.6 Association of PKC-ι and ERK1 in neuroblastoma cells: Since, PKC-ι 
promoted the in-vitro phosphorylation of Elk-1 in ERK-1 dependent manner we 
analyzed the association between PKC-ι and ERK1 in neuroblastoma cells.  
Immnunoprecipitation studies showed that the association between PKC-ι and 
ERK1 coincided with the association of PKC-ι and Elk-1.  The association was 
higher in actively proliferating malignant neuroblastoma LA1-55n cells as 
compared to serum starved cells (Figure.6.8).  This data suggested that PKC-ι 
could regulate is expression by regulating the activity of ERK-1. 
 6.2.7 Subcellular expression ERK1 in neuroblastoma cells: Our data 
suggested that PKC-ι could regulate the activity of ERK1 and its downstream 
target Elk-1.  Thus, the rationale was that there should be a correlation between 
the subcellular expression of the PKC-ι and ERK1.  Analysis of the subcellular 
fractions of actively proliferating malignant neuroblastoma LA1-55n cells 
demonstrated that the expression of ERK1 was higher in the nucleus as 
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compared to the cytoplasm.  In the case of serum starved cell, the expression of 
ERK1 was higher in the cytoplasm (Figure 6.9).  
 
Figure 6.3 Expression of PKC-ι and Elk-1 is higher in actively proliferating 
neuroblastoma cells.  Endogenous levels of PKC-ι in malignant neuroblastoma 
cells, BE(2)-C and LA1-55n and non-malignant cells, LA1-5s were determined by 
Western blot analysis   Equal amounts of cellular proteins (100µg) from actively 
proliferating (50%) and contact inhibited (100% S) cells were loaded in each well 
and immunoblotted for PKC-ι and Elk-1.  β-actin levels were analyzed as a 
loading control.  Data is representative of N=2 independent experiments.  
 
 
 
 
 
57 
 
 
Figure 6.4 Association of PKC-ι and Elk-1 in neuroblastoma cells. PKC-ι (5µg) 
was immunoprecipitated from LA1-5s non-malignant neuroblastoma cells as well 
as BE(2)-C and LA1-55n malignant neuroblastoma cells. The samples were 
subjected to in-vitro kinase activity assay and were analyzed for pElk-1 and pan 
Elk-1 using Western blot analysis. Data is representative of N=2 independent 
experiments.  
 
 
 
Figure 6.5 Association of PKC-ι and Elk-1 in subcellular fractions of 
neuroblastoma cells. PKC-ι (5µg) was immunoprecipitated from BE(2)-C 
malignant neuroblastoma cells.  They samples were analyzed for pan Elk-1 using 
Western blot analysis. Data is representative of N=2 independent experiments.  
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Figure 6.6 A, B Subcellular expression of PKC-ι and Elk-1 in neuroblastoma 
cells. Endogenous levels of PKC-ι and Elk-1 in malignant neuroblastoma cells, 
LA1-55n and BE(2)-C cells were determined by Western blot analysis  Equal 
amounts of cellular proteins (30µg) from subcellular fractions of actively 
proliferating (50%) and contact inhibited (100% S) cells were loaded in each well 
and immunoblotted for PKC-ι and Elk-1. Histone H1 was used as a purity control 
for the experiment.  Data is representative of N=2 independent experiments.  
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Figure 6.7 PKC-ι indirectly phosphorylates Elk-1.  Recombinant active PKC-ι 
(0.5μg) and active Elk-1 (0.5μg) in the presence (column 3) and absence 
(column 1) of recombinant active ERK1 were subjected to an in-vitro kinase 
activity assay. ERK1 and Elk-1 (second column) was the positive control.  The 
proteins were then separated by SDS-PAGE and Western blotted to determine 
the phosphorylation of Elk-1 at T170.  Data represents N=2 independent 
experiments.   
 
 
Figure 6.8 Association of PKC-ι and ERK1 in neuroblastoma cells. PKC-ι (5µg) 
was immunoprecipitated from LA1-5s non-malignant neuroblastoma cells as well 
as BE(2)-C and LA1-5s malignant neuroblastoma cells. The samples were 
subjected to in-vitro kinase activity assay and were analyzed for pERK1 and pan 
ERK1 using Western blot analysis. Data is representative of N=2 independent 
experiments.   
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Figure 6.9 Subcellular expression ERK1 in neuroblastoma cells. Endogenous 
levels of ERK1 in malignant neuroblastoma LA1-55n cells were determined by 
Western blot analysis  Equal amounts of cellular proteins (30µg) from subcellular 
fractions of actively proliferating (50%) and contact inhibited (100% S) cells were 
loaded in each well and immunoblotted for ERK1 and β-actin.   
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6.3 Summary 
Based on our data, we hypothesize that in contrast to Bcr-Abl mediated 
regulation of PKC-ι, PKC-ι can directly regulate the transcriptional activity of Elk-
1, thereby self-regulating its expression. 
Our hyphothesis can be summarized by the following diagram: 
 
 
Figure 6.10 Self-regulation of PKC-ι. We hypothesize that PKC-ι translocates into 
the nucleus in actively proliferating neuroblastoma cells where it activates ERK1.  
This promotes the activation of its downstream target Elk-1 which subsequently 
upregulates the expression of PKC-ι.   
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CHAPTER 7 
DISCUSSION AND FUTURE DIRECTIONS 
7.1 Discussion 
Very little research has been conducted using PKC-ι specific inhibitors.  
To date, the only compounds identified as inhibitors of atypical PKC isoforms are 
aurothiomalate (ATM) and aurothioglucose.  ATM, which is currently in phase I 
clinical trial evaluation for lung cancer (sponsored by NCI) has IC50 ranging from 
~0.3 µM – >100 μM [111].  However, ATM has not been shown to act specifically 
on PKC-ι versus ζ, and the mechanism of action for ATM is not fully understood, 
as shown by its off target effects.  PKC-ι and PKC-ζ are 84% homologous with 
respect to the amino acid sequences of their catalytic domain [56] making it very 
difficult to synthesize an inhibitor that is specific.  Nevertheless, in this study the 
sequence targeted for molecular docking was amino acid residues 469-475 
(glutamine, isoleucine, arginine, isoleucine, proline, arginine and serine).  The 
molecular docking method was based on an experimental design that included 
rapid functional testing of specificity between PKC isoforms as the primary step 
of in vitro screening.  This important aspect of the approach eliminates 
candidates that bind the ATP binding pocket (which is conserved between PKC 
isoforms).  Although it is straightforward to model numerous potential interactions 
by molecular docking in silico, such as docking molecules into the ATP binding 
site or other surfaces, our approach pinpointed the most diverse structural 
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elements in PKC-ι and purposefully evaluated specificity in vitro to avoid 
compounds that interact with structural features that are common to PKC 
isoforms such as the ATP binding pocket.  This directed molecular docking 
approach has been successfully used in a number of studies [142].  The current 
study established the chemotherapeutic potential of the novel PKC-ι inhibitor, 
ICA-1.  Comparative study of ICA-1 and ATM showed that ICA-1 specifically 
inhibited the activity of only PKC-ι, whereas ATM exhibited inhibitory effects on 
both PKC-ι and PKC-ζ, suggesting non-specificity of the drug.  The IC50 of ATM 
was 100µM which is 1000 times more than the IC50 for ICA-1.  Furthermore, the 
PIP3 activation assay showed that ICA-1 specifically inhibited the activity of PKC-ι 
with an IC50 of 0.01 µM.  Since this assay measures the femtomoles of (γ-32P) 
ATP transferred, it was possible to measure the efficacy of ICA-1 over a broad 
range of concentrations yielding the most sensitive data.  However, we did not 
test the inhibitory effect of ATM using PIP3 activity assay because lower 
concentrations of ATM did not exhibit any effects on the activity of either PKC-ι or 
PKC-ζ.  The structure of ICA-1 is similar to FDA approved chemotherapeutic 
drug Fludarabine, administered as 5′-nucleotide monophosphate [143].  Thus, we 
speculate that ICA-1 may be transported into the cell by a mechanism that 
utilizes a nucleoside transporter similar to Fludarabine [144]. 
Previously, we found that PKC-ι is overexpressed in actively proliferating 
prostate cancer and glioma cells [71, 73].  Similarly, we found higher expression 
of PKC-ι in adrenal neuroblastoma tissue as well as neuroblastoma cells 
suggesting the involvement of PKC-ι in the proliferation of neuroblastoma cells.  
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Phenotypically, neuroblastoma cells can be divided into 3 distinct groups: 
sympathoadrenal neuroblasts (N-type that form slow growing tumors), non-
neuronal precursor cells (S-type which are non-malignant) and I-type which are 
morphologically intermediate to that of N and S cells.  I-type cells possess the 
biochemical properties of both N and S cells [145].  Thus, the rationale behind 
our choice of BE(2)-C cells (I-type) was to ensure that our results are 
representative of all the major neuroblastoma phenotypes.  The S-type have 
been shown to be normal neuronal cells [146].  Thus, LA1-5s cells were used as 
control to analyze the toxicity of ICA-1. 
To determine the mechanism underlying the anti-proliferative action of 
ICA-1, we first identified a signaling pathway by which PKC-ι may promote 
constitutive proliferation of BE(2)-C cells.  We focused on investigating the role of 
cdks since they are involved in regulation of cell cycle progression [78]. Our data 
suggest that PKC-ι is an in-vitro Cdk7 kinase.  Endogenously, PKC-ι directly 
associated and phosphorylated both Cdk7 as well as its downstream target cdk2 
suggesting that PKC-ι is regulating or promoting neuroblastoma cell proliferation 
via the PKC-ι/Cdk7/cdk2 pathway.  Hence, this pathway was targeted to verify 
the efficacy of ICA-1. 
We were not able to obtain the effects of ICA-1 on the cell cycle because 
of the BE(2)-C cells grow in clusters.  The results obtained from cell cycle 
analysis by flow cytometry yielded a very high percentage of aggregates making 
it impossible to determine the significance of the data (n=8) (data not shown). 
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Collectively, our data exhibit the potential of ICA-1 as a novel PKC-ι 
inhibitor.  The efficacy of ICA-1 at such low concentration (0.1µM) and its 
negligible effect on normal neuronal cells suggests its potential as a 
chemotherapeutic with little toxicity.  Therefore, future studies will investigate the 
effects of ICA-1 on an in-vivo mouse model to establish the feasibility of 
advancing ICA-1 to clinical trials.  Furthermore, PKC-ι expression should be 
useful as a biomarker for neuroblastoma when treating patients with anti-PKC-ι 
therapy (with ICA-1 or one of its derivatives) for personalized medicine.  
 Bcr-Abl has been shown to regulate the activation of the transcription 
factor ELK-1 which in turn regulates the expression of PKC-ι [121].  Alternatively, 
we hypothesize that PKC-ι self regulates its expression by indirectly regulating 
the activity of ELK-1.  Our preliminary data shows that the expression of PKC-ι 
and Elk-1 were higher in actively proliferating LA1-5S (non-malignant), BE(2)-C 
and LA1-55n (malignant )neuroblastoma cells.  Immunoprecipitation studies 
show that association of PKC-ι with phosphorylated Elk-1 was more robust in 
these cells suggesting a crosstalk between the two proteins.  Analysis of the 
subcellular association of these two proteins revealed increased association 
between PKC-ι and Elk-1 in the nucleur fraction of actively proliferating BE(2)-C 
cells as compared to cytoplasm.  Interestingly, the nuclear expression of PKC-ι 
was also found to be higher in these cells, sugeesting that PKC-ι translocated to 
the nucleus in actively proliferating cells and regulated the transcriptional activity 
of Elk-1.  Although, recombinant active PKC-ι did not phosphorylate recombinant 
active Elk-1, it increased the phosphorylation of Elk-1 in the presence of ERK1, 
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an upstream kinase of Elk-1 in the Bcr-Abl mediated PKC-ι regulatory pathway.  
Thus, our data suggested that ERK1 was integral to the self-regulatory activity of 
PKC-ι.  Furthermore, expression of ERK1 was also found to be higher in the 
nuclear fraction of our actively proliferating model cell systems. 
In conclusion, we propose a novel self-regulatory mechanism of PKC-ι in 
neuroblastoma cells.  We hypothesize that the self-regulation of PKC-ι 
commences with the translocation of PKC-ι into the nucleus where it promotes 
the activation of ERK1.  This culminates in increased activation of Elk-1, a 
downstream target of ERK1 and subsequent upregulation in the expression of 
PKC-ι.  Our hypothesis can be summarized as PKC-ι/ ERK1/ Elk-1/ PKC-ι 
pathway (Figure 6.10) 
7.2 Suggestions for future studies 
• Determine the potency of ICA-1 in-vivo 
• Study the effect of ICA-1 on other cancers models such as  
prostate, breast cancer, ovarian cancer, etc. 
• Analyze the pharmacodynamics and pharmacokinetics of ICA-1 
• Examine the effect of ICA-1 on other Protein kinase C isozymes 
• Evaluate the effect of ICA-1 on other protein kinases 
• Investigate the effect of other protein kinase C in neuroblastoma 
• Analyze the role of PKC-ι in neuroblastoma cell survival 
• Investigate the effect of ICA-1 on the self regulation of PKC-ι 
• Study the effect of PKC-ι on the regulation of other members of the Ets  
family.  
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CHAPTER 8 
MATERIALS AND METHODS 
8.1 Reagents 
ICA-1 or [4-(5-amino-4-carbamoylimidazol-1-yl)-2,3-
dihydroxycyclopentyl]methyl dihydrogen phosphate was synthesized and 
purchased from Southern Research Institute (Birmingham, AL).  It was dissolved 
in sterile distilled water (vehicle) before use.  Recombinant PKC-ι and 
recombinant PKC-ζ active enzymes were purchased from Millipore (Temecula, 
CA).  Myelin basic protein (MBP) was purchased from Sigma (St. Louis, MO).  
PKC-ι antibody was purchased from BD Biosciences (San Jose, CA).  The 
antibodies to phospho-MBP (pMBP) (Thr 98), MBP, PKC-ζ, pElk-1 were 
purchased from Millipore. PKC activity assay kit was purchased from Assay 
Designs (Ann Arbor, MI). For the 32P labeling, recombinant PKC-ι from BioVision 
(Mountain View, CA), PIP3  [Phosphatidylinositol (3,4,5)-trisphosphate] from 
Avanti Polar Lipids (Alabaster, Al), (γ-32P)ATP from NEN Life Science Products 
Inc. (Boston, MA) and PKC-ε Pseudosubstrate from (Invitrogen Inc.) were used.  
The antibodies to Cdk7, phospho-cdk2 (pcdk2, Thr 160), Caspase-3, Elk-1, ERK-
1 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). pCdk7 (Thr 
170) antibody was purchased from Abcam (Cambridge, MA).  The antibodies 
purchased from Cell Signaling were: PARP and cleaved PARP.  Enhanced 
chemiluminescence (Supersignal West Pico Chemiluminescent Substrate) was 
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purchased from Pierce (Rockford, IL).  Dulbecco’s phosphate buffered saline 
without Mg2+ and Ca2+ (DPBS) and Trypsin-EDTA (ethylenediaminetetraacetic 
acid) solution was purchased from Fisher Scientific (Norcross, GA).   
8.2 Cell culture 
Phenotypically, neuroblastoma cells can be divided into 3 distinct groups: 
sympathoadrenal neuroblasts (N-type that form slow growing tumors), non-
neuronal precursor cells (S-type which are non-malignant) and I-type which are 
morphologically intermediate to that of N and S cells.  I-type cells possess the 
biochemical properties of both N and S cells [145].  The S-type have been shown 
to be normal neuronal cells [146].  Thus, LA1-5s cells were used as control to 
analyze the toxicity of ICA-1. 
BE(2)-C human neuroblastoma cells, were obtained from the American 
Tissue Culture Collection (Rockville, MD).  These cells are clones of the SK-N-
BE(2) human neuroblastoma cell line [147].  Phenotypically, they are classified 
as I-type neuroblastoma cells [145].  [145].   LA1-5s and LA1-55n cells were 
obtained from Dr. Robert Ross’ laboratory in Fordham University, NY.  Cells (2x 
106) were grown as a monolayer in 75 cm2 tissue culture flasks and maintained 
at 37˚C in a humidified atmosphere comprised of 5% CO2.The complete growth 
medium was 89% by volume of 1:1 mixture of Eagle's Minimum Essential 
Medium from ATCC and Ham's F12 Medium from Invitrogen corporation 
(Carlsbad, CA).  Additionally, the media was supplemented with 10% fetal bovine 
serum from ATCC and 1% antibiotics (Penicillin 10 U/ml and streptomycin 
10µg/ml from Fisher Scientific, Norcross, GA.  
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8.3 Atypical PKC profiling 
Preliminary work was performed on neuroblastoma tissues obtained from 
the Nationwide Children's Hospital Biopathology Center.  The expression of PKC-
ι in adrenal neuroblastoma (n=11) was compared to normal adrenal biopsies 
(n=11).  Furthermore, actively proliferating BE(2)-C cells (50% confluent) were 
harvested and cell lysates were prepared as described in the 
‘Immunoprecipitation and Western Blot analysis’ section.  Another set of cells 
were grown until contact inhibition was achieved (100% confluent).  
Subsequently, the cells were washed twice with DPBS, followed by addition of 
starved media (absence of fetal bovine serum) for an additional 48 hours.  Cells 
were then harvested and cell lysates were prepared.  Proteins (100µg) from both 
sets of cell lysates were separated by SDS-PAGE and immunoblotted for PKC-ι 
and PKC-ζ with specific antibodies. 
8.4 Cell fractionation and Western Blot Analysis 
Cells were placed on ice to terminate the incubation.  The cells were 
washed twice with DPBS and then scraped at 4˚C, resuspended and sonicated in 
300μl of homogenization buffer (50 mM HEPES at pH 7.5), 150 mM NaCl, 1 mM 
EDTA and 2 mM EGTA [glycol-bis(2-aminoethylether)-N, N, N’, N’-tetraacetic 
acid], 0.5% Triton-X 100, 1 mM sodium orthovanadate, 0.5 M NaF, 0.2 M PMSF 
(phenylmethylsulphonylfluoride), 1mM DTT (dithiothreitol) and 0.15 U/ml 
aprotinin [148].  The cell suspension was centrifuged at 16,000 g for 30 minutes 
to obtain cell extracts.  The protein content was measured according to Bradford 
[149].  Protein samples were separated by 12% on sodium dodecyl sulfate-
70 
 
polyacrylamide gel electrophoresis (SDS-PAGE) (1.5mm thick gel) using Protean 
II xi 16cm gel loading system (BioRad) and electrophoresed at 160volts and 
subsequently transblotted by electroblotting with transfer buffer 100 ml of 10 x tris 
glycine (0.25 M tris and 1.92 M glycine) and 20% methanol in 1 L of distilled 
water and electroblotted for one hour at 24 volts.  For Western blot analysis, 
each blot was blocked for 1 hour with 5% (w/v) fat-free dry milk in tris-buffered 
saline with 0.05% tween-20 (TBST) solutions at room temperature.  Protein 
bands were probed with primary antibody in 5% milk in blocking buffer at 4°C 
overnight.  The primary antibodies dilutions were 1:1000-1:5000. Membranes 
were subsequently washed three times for 15 minutes with TBST.  Secondary 
antibodies such as horseradish-peroxidase-conjugate anti-mouse, anti-rabbit or 
anti-goat were diluted 1:1000 in 5% milk TBST.  The membranes were incubated 
with secondary antibody (1:5000) at room temperature for 1 hour.  
Immunoreactive bands were visualized with SuperSignal West Pico 
Chemiluminescent substrate. 
8.5 Densitometry 
The intensity of each band was measured using the Quantity one, 1-D 
analysis software (BioRad Laboratories).  In order to derive the correct intensity 
of each band, the background intensity was subtracted from the band intensity.  
Mean absorbance of three independent studies were compared by means of 
Student’s t-test to determine the statistical significance of the data. 
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8.6 Inhibition of PKC-ι with siRNA 
The siRNA was a pool of 3 target-specific 19-25 nucleotides siRNAs 
designed to knock down PKC-iota gene expression.  Each vial contains 3.3 nmol 
of lyophilized siRNA, sufficient for a 10 μM solution once resuspended using 
company protocol.  Their mRNA sequences were: 
663:5-CAAGCCAAGCGUUUCAACA-3’ 
       5’-UGUUGAAACGCUUGGCUUG- 3’ 
729: 5’-GGAACGAUUGGGUUGUCAU-3’ 
         5’-AUGACAACCCAAUCGUUCC-3’ 
2137:5’-CCCAAUAUCUUCUCUUGUA-3’ 
        5’-UACAAGAGAAGAUAUUGGG-3’ 
These were designed by Santa Cruz Biotechnology.  BE(2)-C cells (5 x 
104) were plated and grown in 25 cm2 tissue culture plates.  Twenty four hour 
post-plating cells were transfected with either control siRNA sequences 
(containing scrambled sequence which does not lead to specific degradation of 
any known cellular mRNA; sequence not revealed by Santa Cruz Biotechnology) 
or PKC-ι gene silencing sequences (150nM).  Cell viability was determined over 
a time period of 24, 48 and 72 hour.  Cell viability was performed as using Trypan 
Blue Exclusion assay.  To analyze the effect of siRNA on PKC-ι expression, cells 
(2x105) were treated with PKC-ι siRNA for 48 hours and then total lysate were 
prepared.  The protein (100µg) was separated by SDS-PAGE followed by 
Western blot to determine the expression of PKC-ι and PKC-ζ.  To determine the 
effect of PKC-ι siRNA on the phosphorylation of Cdk7, the protein was 
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immunoprecipitated using Cdk7 antibody (5µg) and subjected to Western blot 
analysis. 
8.7 In-vitro kinase activity assay to analyze the phosphorylation of Cdk7 by 
PKC-ι 
The recombinant active PKC-ι (0.5μg) and Cdk7 (0.5µg) purchased from 
Millipore (Temecula, CA) were suspended in 200μl of PKC kinase buffer [150] to 
test the ability of PKC-ι as an in-vitro Cdk7 kinase.  The reaction was terminated 
after incubation for 10 min at 30°C by placing the samples in ice and adding 
sample loading buffer.  Samples were then fractionated by SDS-PAGE and 
immunoblotted via Western Blot analysis.  
8.8 Immunoprecipitation 
Cells were placed on ice to terminate the incubation.  The cells were 
washed twice with DPBS and then scraped at 4˚C, resuspended and sonicated in 
300μl of homogenization buffer (50 mM HEPES at pH 7.5), 150 mM NaCl, 1 mM 
EDTA and 2 mM EGTA [glycol-bis(2-aminoethylether)-N, N, N’, N’-tetraacetic 
acid], 0.5% Triton-X 100, 1 mM sodium orthovanadate, 0.5 M NaF, 0.2 M PMSF 
(phenylmethylsulphonyl-fluoride), 1mM DTT (dithiothreitol) and 0.15 U/ml 
aprotinin [148].  The cell suspension was centrifuged at 16,000 g for 30 minutes 
to obtain cell extracts.  The protein content was measured according to Bradford 
[149].  Approximately 200μg of protein was immunoprecipitated with affinity 
purified antibodies (5μg).  Cell lysates were first subjected to pre-clearance by 
incubation with agarose beads for 30 minutes at 4°C.  The cell lysates were 
subsequently incubated with 5μg of either PKC-ι or Cdk7 antibody or both in case 
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of co-immunoprecipitation.  The immune complexes were rocked overnight at 
4°C and further incubated at 4°C for 2 hours with IgG-agarose beads specific to 
the strain of primary antibody.  Post incubation, the beads were washed three 
times with 1mL of complete lysis buffer.  Samples were then separated on 12% 
SDS-PAGE and transblotted onto a nitrocellulose membrane.  The proteins were 
detected by Western blot analysis.   
8.9 Database preparation 
The National Cancer Institute/Developmental Therapeutics Program 
(NCI/DTP) maintains a repository of 139,644 samples (the plated compound set).  
The three-dimensional coordinates for the NCI/DTP plated compound set in the 
MDL sd format was converted to the mol2 format by the program SDF2MOL2 
(UCSF). Partial atomic charges for the ligands were calculated using SYBDB 
(UCSF) and added to the plated compound set mol2 file.  This was performed by 
David Ostrov, Ph. D. at the University of Florida. 
8.10 Molecular docking 
Molecular docking was done by selecting specific structural pockets in 
PKC-ι protein that may be suitable for interactions with drug-like small molecules.  
Molecular docking simulations where each one of approximately 300,000 small 
molecules (MW < 500) is positioned in the selected structural pocket and scored 
based on predicted polar (e.g., H bond) and non-polar (e.g. Van der Waal’s) 
interactions.  The 30 top scoring compounds for each selected structural pocket 
were obtained for use in functional assays.  The grid based scoring method sums 
the attractive and repulsive forces between atoms in each docked small molecule 
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and the site selected for molecular docking. Interactions between charges on 
atoms in ICA-1 with amino acids are computed as an electrostatic score. The 
electrostatic score and van der Waals scores are summed to generate an overall 
energy score which was used to rank the highest scoring compounds. 
Docking calculations were performed with the October 15, 2002 version of 
DOCKv5.1.0.  The coordinates for the crystal structure PKC, PDB code 1ZRZ, 
were used.  The molecular surface of the structure was explored using sets of 
spheres to describe potential binding pockets.  The spheres literally fill in the 
available pocket spaces where a ligand might be able to form a complex.  DOCK 
uses the spheres as guides to search for orientations of each molecule that fit 
into the selected sites.  The sites selected for molecular docking were defined 
using the SPHGEN/SITESELECTOR programs and filtered through the 
CLUSTER program.  The SPHGEN program generates an unbiased grid of 
points that reflect the actual shape of the selected site.  The CLUSTER program 
groups the selected spheres to define the points that are used by DOCK to 
match (superimpose) potential ligand atoms with spheres.  Twenty two spheres 
were used to define the PKC-ι site for molecular docking.  Each compound in the 
NCI/DTP repository was positioned in the selected site in 1000 different 
orientations.  Intermolecular AMBER energy scoring (vdw + columbic), contact 
scoring and bump filtering implemented in DOCKv5.1.0. PYMOL were used to 
generate molecular graphic images.  All molecular docking jobs were performed 
on a high performance supercomputer at the University of Florida running linux.  
This was performed by David Ostrov, Ph. D. at the University of Florida. 
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8.11 Phosphorylation of MBP by recombinant active PKC-ι or recombinant 
active PKC-ζ enzymes 
The PKC-ι or PKC-ζ (0.01μg/μl) was incubated with different 
concentrations of ICA-1 (0.1 µM, 1 µM or 5 µM) for 10 min at 4°C.  This was 
followed by incubation at 30°C in 200μl of PKC kinase buffer [150] to test the 
ability of these PKC isoforms to phosphorylate a final concentration of 0.025 
mg/ml MBP, a known substrate for PKCs [112].  The reaction was terminated 
after 10 min by placing the samples in ice and adding sample loading buffer.  
Samples were then fractionated by SDS-PAGE and immunoblotted. 
8.12 PKC activity assay kit 
The selectivity of ICA-1 and ATM for PKC-ι versus PKC-ζ were compared 
using a PKC activity assay kit (Assay Designs).  The recombinant active PKC-ι 
(0.01µg) or PKC-ζ (0.01µg) were incubated with different concentrations of ICA-1 
(0.1 µM, 1 µM or 5 µM) or  ATM (0.01µM, 0.1µM, 1µM or 100µM) for 10 min at 
4°C followed by incubation with phosphatidylserine (5μg) and ATP (0.0025 
mg/ml) for 30 min at 30°C. The remaining steps were per the manufacturer’s 
protocol. 
8.13 32P labeling 
Briefly, 0.01µg of recombinant active PKC-ι was treated with different 
concentrations of ICA-1 for 10 min at 4°C before adding 10 fM PIP3 , 
phosphatidylserine (4µg), (γ-32P)ATP (50 µmol/L) and as substrate, serine analog 
of the PKC-ε pseudosubstrate (40 µmol/L).  This mixture was suspended in 100µl 
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of reaction mixture composed of Tris-HCl (50 mmol/L at pH 7.5), (sodium 
orthovandate) Na3VO4 (100µmol/L), (sodium phosphate) Na2P2O7 (100µmol/L), 
(sodium fluoride)NaF (1 mmol/L), (phenylmethanesulfonylfluoride) PMSF 
(100µmol/L) and (magnesium chloride) MgCl2 (5 mmol/L) followed by incubation 
for 10 min at 30°C. After incubation, the 32P labeled substrate was trapped on P-
81 filter paper and counted in a liquid scintillation counter.  
8.14 Competitive inhibitory assay 
The assay was performed using an ELISA plate which was coated by 
incubating with1µg of phospho-MBP (pMBP) (T98) overnight at 4⁰C.  The 
antibody dilution buffer used was 3% BSA (Bovine serum albumin).  Twenty-four 
hours post-incubation, the wells were washed 3-4 times with DPBS buffer and 
blocked with 200µl of antibody dilution buffer at room temperature for 2 hour.  
Recombinant active PKC-ι (0.01μg/μl) was incubated with or without ICA-1 
(1 µM) for 10 min at 4°C prior to addition of 50μl of PKC kinase buffer [150] to 
test the inhibitory effects of ICA-1 on PKC-ι activity utilizing varying 
concentrations of MBP (0.0025 mg/ml, 0.05 mg/ml, 0.010 mg/ml and 0.02 
mg/ml).  This reaction was performed in separated tubes and terminated after 10 
min incubation at 30°C by placing the samples in ice.  The reaction cocktail was 
subsequently transferred to the ELISA plate (primary antibody bound) and 
incubated at room temperature for 2 hours.  The wells were washed 3-4 times 
with DPBS buffer and incubated with secondary antibody at room temperature for 
1 hour.  Subsequently, wells were washed 3-4 times with DPBS buffer and 
incubated with tetramethylbenzidine (TMB) reagent for 1 hour at room 
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temperature.  Acid stop solution was added to each well and the absorption was 
measured at 450nm. 
8.15 In-vitro kinase activity assay to analyze the effect of ICA-1 on the 
phosphorylation of recombinant Cdk7 by recombinant PKC-ι 
The recombinant active PKC-ι (0.5μg) and Cdk7 (0.5µg) were purchased 
from Millipore (Temecula, CA) and were suspended in 200μl of PKC kinase 
buffer [150] to test the ability of these PKC-ι as an in-vitro Cdk7 kinase.  The 
same reaction was repeated in the presence of ICA-1 drug (0.1uM, 1µM and 
5uM).  In both the experiments, the reaction was terminated after incubation for 
10 min at 30°C by placing the samples in ice and adding sample loading buffer.  
Samples were then fractionated  
8.16 Cell viability assay 
LA1-5s and BE(2)-C cells (5x 104) were cultured in 25 cm2 tissue culture 
flasks.  Twenty-four hours post plating, fresh media was supplied and cells were 
incubated with either equal volume of sterile water (vehicle control) or ICA-1 
(0.04µM to 0.1µM).  Following the initial exposure to ICA-1, additional doses of 
sterile water or ICA-1 were supplied every 24 hour during the three day 
incubation period.  In order to analyze the effect of ATM (aurothiomalate) on cell 
viability, LA1-5s and BE(2)-C cells were treated with DPBS (vehicle control) or 
ATM (0.01µM - 100µM).  Cell viability was determined at 24, 48 and 72 hours.  
Cell viability was quantified using a Trypan blue exclusion assay. 
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8.17 Analysis of apoptosis 
The first method used was DAPI staining.  BE(2)-C cells were grown in 
glass chamber slide (BD Bioscience)  and treated with ICA-1 as in the cell 
viability assay.  Forty eight hours post-treatment, cells were washed three times 
with cold 1x DPBS, fixed with 1:1 methanol and acetone (5 minutes at -20°C) and 
washed again 3 times with 1x DPBS. Cell nuclei were visualized in mounting 
medium containing DAPI (blue, Vector Laboratories, Inc) using a Nikon Eclipse 
TE2000-U microscope.  Pictures were captured by NIS-Elements F Version 2.10.  
The second method used was TUNEL Assay.  DNA fragmentation was 
visualized by means of fluorescence staining using a TUNEL apoptosis detection 
kit according to the manufactures instructions.  BE(2)-C cells were grown and 
treated with ICA-1 as explained for DAPI staining.  At 48 hours, the cells were 
fixed using 4% paraformaldehyde in 0.1 M NaH2PO4 , pH 7.4, followed by 
incubation for 60 minutes in a reaction mixture composed of biotin-dUTP and 
terminal deoxynucleotidyl transferase.  The sample was then incubated with 
fluorescein isothiocyanate-avidin (FITC-avidin) for 30 minutes.  The positively 
stained cells were observed and photographed for DAPI staining.  
Finally, the apoptosis was determined by analysis of Caspase-3 and 
PARP cleavage.  BE(2)-C cells were cultured in 100 mm tissue culture flasks and 
treated with ICA-1 as in the cell viability assay.  Protein (200µg) was separated 
by SDS-PAGE and immunoblotted.  
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8.18 Preparation of cytoplasmic and nuclear extracts 
 Cells were washed twice with cold PBS and resuspended in hypotonic b 
buffer.  The buffer is comprised of 50 mM HEPES (pH 7.4), 10 mM KCl, 1 mM 
EDTA, 1 mM EGTA, 1 mM dithiothreitol, 1 mM PMSF, 2.5 lg/m leupeptin, 0.15 
U/ml aprotinin.  The lysates were then centrifuged at 30 min 4000g for 30 min at 
4 ˚C.  The cytoplasmic fraction (supernatant) was separated and collected.  The 
nuclear fraction (pellet) was suspended in a Buffer containing 400 mM KCl and 
0.5% Triton X-100. The lysates were then centrifuged at 14,000g for 30 min at 
4˚C and the supernatant containing nuclear extracts was collected.   
8.19 In-vitro kinase activity assay to analyze the phosphorylation of 
endogenous Elk-1 by PKC-ι 
PKC-ι (0.5μg) was immunoprecipitated from cell lysates of BE(2)-C 
malignant neuroblastoma cells and T98G malignant glioma cells. And suspended 
in 200μl of PKC kinase buffer [150] to test the ability of PKC-ι to phophorylate 
Elk-1.  The reaction was terminated after incubation for 10 min at 30°C by placing 
the samples in ice and adding sample loading buffer.  Samples were then 
fractionated by SDS-PAGE and immunoblotted via Western Blot analysis.  
8.20 In-vitro kinase activity assay to analyze whether PKC-ι directly 
phosphorylates recombinant Elk-1 
Recombinant active PKC-ι (0.5μg) and recombinant active Elk-1 (0.5μg) 
were subjected to an in-vitro kinase activity assay in the presence and absence 
of recombinant active ERK1.  The phosphorylation of Elk-1 by ERK1 was used 
as the positive control.  The proteins were then separated by SDS-PAGE and 
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Western blotted to determine the phosphorylation of Elk-1.  Data represents N=2 
independent experiments.  
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